Nexavar News and Research

RSS
Encouraging data from perifosine Phase 2 studies in advanced leukemia, Hodgkin's lymphoma

Encouraging data from perifosine Phase 2 studies in advanced leukemia, Hodgkin's lymphoma

AVEO to present data on tivozanib Phase 1b trial for breast cancer at SABCS Symposium

AVEO to present data on tivozanib Phase 1b trial for breast cancer at SABCS Symposium

Apricus files protocol of PrevOnco Phase 3 clinical trial for FDA SPA program

Apricus files protocol of PrevOnco Phase 3 clinical trial for FDA SPA program

AVEO announces results from tivozanib Phase 1b clinical trial for advanced gastrointestinal cancers

AVEO announces results from tivozanib Phase 1b clinical trial for advanced gastrointestinal cancers

AVEO commences enrollment in Phase 1b combination trial of tivozanib with oral capecitabine in advanced tumors

AVEO commences enrollment in Phase 1b combination trial of tivozanib with oral capecitabine in advanced tumors

Data from AVEO's tivozanib-FOLFOX6 combination Phase 1b trial presented at 22nd EORTC-NCI-AACR

Data from AVEO's tivozanib-FOLFOX6 combination Phase 1b trial presented at 22nd EORTC-NCI-AACR

Positive results from Ardea's RDEA594 combination study with febuxostat or allopurinol for gout

Positive results from Ardea's RDEA594 combination study with febuxostat or allopurinol for gout

Apricus receives $733,437 grants under QTDP program

Apricus receives $733,437 grants under QTDP program

FDA approves cancer drug Afinitor for treatment of rare genetic disorder

FDA approves cancer drug Afinitor for treatment of rare genetic disorder

Pfizer's Sutent stands as first-line setting for treating renal cell carcinoma: Survey

Pfizer's Sutent stands as first-line setting for treating renal cell carcinoma: Survey

AVEO presents tivozanib Phase 2 study results at ESMO Congress

AVEO presents tivozanib Phase 2 study results at ESMO Congress

Onyx Pharmaceuticals announces delay in NDA filing for carfilzomib

Onyx Pharmaceuticals announces delay in NDA filing for carfilzomib

Bayer HealthCare, Onyx to present data on Nexavar tablets at ESMO Congress

Bayer HealthCare, Onyx to present data on Nexavar tablets at ESMO Congress

AVEO Pharmaceuticals to present tivozanib Phase 2 study results at IKCS Symposium

AVEO Pharmaceuticals to present tivozanib Phase 2 study results at IKCS Symposium

Jennerex reports positive interim data from trial of JX-594 and sorafenib for liver cancer

Jennerex reports positive interim data from trial of JX-594 and sorafenib for liver cancer

Onyx enters commercialization agreement with Ono for carfilzomib and ONX 0912 development program

Onyx enters commercialization agreement with Ono for carfilzomib and ONX 0912 development program

Ardea Biosciences second-quarter total revenues decline to $3.5 million

Ardea Biosciences second-quarter total revenues decline to $3.5 million

Onyx reports positive results from carfilzomib Phase 2b 003-A1 study in multiple myeloma

Onyx reports positive results from carfilzomib Phase 2b 003-A1 study in multiple myeloma

Human Genome Sciences second-quarter revenues increase to $38.8 million

Human Genome Sciences second-quarter revenues increase to $38.8 million

Onyx begins Phase 3 trial of carfilzomib in combination with lenalidomide, dexamethasone for relapsed myeloma

Onyx begins Phase 3 trial of carfilzomib in combination with lenalidomide, dexamethasone for relapsed myeloma